Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application - Pfizer (NYSE:PFE), V

Valneva (VALN) stock surges after EMA validates MAA for Lyme disease vaccine candidate developed with Pfizer (PFE). Phase 3 trial showed efficacy and no safety concerns, pending regulatory approval.